Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Biology Reports"
DOI: 10.1007/s11033-019-04921-5
Abstract: Immunogenicity of therapeutic proteins is one of the main challenges in disease treatment. l-Asparaginase is an important enzyme in cancer treatment which sometimes leads to undesirable side effects such as immunogenic or allergic responses. Here,… read more here.
Keywords: protein; erwinia chrysanthemi; immunogenicity; chrysanthemi asparaginase ... See more keywords
Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and Translational Science"
DOI: 10.1111/cts.13499
Abstract: JZP458 is a recombinant Erwinia chrysanthemi asparaginase for patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who have developed hypersensitivity to Escherichia coli–derived asparaginases. A population pharmacokinetic (PopPK) model was developed for intramuscular (i.m.) JZP458… read more here.
Keywords: recombinant erwinia; jzp458; patients acute; asparaginase ... See more keywords